A leading pharmaceutical company with a novel disease-modifying product was seeking Government subsidy and wanted to better communicate the broader value of the drug, beyond the clinical measures captured through the clinical trial.
HTANALYSTS helped a global medical device company with an innovative targeted interventional approach obtain market access and provider reimbursement in western European countries.
The Australian Department of Health engaged HTANALYSTS to develop guidelines that establish a common national approach within and between mental health organisations and services in Australia.